Innovative HIV Strategies: Inclusive Trials and Long-Acting Medications
TL;DR Summary
The fight against HIV/AIDS is advancing with new long-acting PrEP options, such as Lenacapavir and Cabotegravir, which require less frequent dosing and could improve accessibility and adherence. These innovations, supported by organizations like the Gates Foundation, aim to overcome barriers to daily medication use and enhance prevention efforts. While the search for an HIV vaccine continues, these developments offer multiple layers of protection, crucial for reducing transmission and saving lives globally.
- From once a day to twice a year Gates Notes
- Gilead Sciences: Designing Inclusive Clinical Trials in an Effort To Upend the HIV Epidemic AccessWire
- A call for urgent action in navigating the complex landscape of long-acting HIV medications Daily Maverick
- Achieving the promise of new PrEP products to prevent HIV FHI 360
- Expand choices for Women, Prevent New HIV Infections in Africa Global Issues
Reading Insights
Total Reads
0
Unique Readers
22
Time Saved
4 min
vs 5 min read
Condensed
92%
873 → 71 words
Want the full story? Read the original article
Read on Gates Notes